Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSY-S extension study of anifrolumab in systemic sclerosis
MOH_2026-09-14_017034Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of anifrolumab in systemic sclerosis (SSc), sponsored by AstraZeneca. Primary endpoint: Long-term safety and tolerability of anifrolumab. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on MOH_2026-09-14_017034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-14_017034.